Safety and Efficacy of Restarting ICIs After Clinically Significant Immune-Related Adverse Events in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Safety and Efficacy of Restarting Immune Checkpoint Inhibitors After Clinically Significant Immune-Related Adverse Events in Metastatic Renal Cell Carcinoma
J Immunother Cancer 2020 Feb 01;8(1)e000144, S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, JA Steinharter, PV Nuzzo, R Flippot, N Martinez-Chanza, X Wei, BA McGregor, MD Kaymakcalan, DYC Heng, MA Bilen, TK Choueiri, LC HarshmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.